Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

8.0%

2 terminated out of 25 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

28%

7 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed with results

Key Signals

2 with results87% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (4)
P 1 (1)
P 2 (2)
P 3 (2)
P 4 (5)

Trial Status

Completed13
Recruiting4
Unknown3
Terminated2
Withdrawn2
Enrolling By Invitation1

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT05040373Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

NCT07250243Completed

Turkish Validation and Reliability of the John Hopkins In-Room Independence Scale

NCT07152197Not ApplicableRecruitingPrimary

Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)

NCT06414746Completed

Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia

NCT05950867Not ApplicableRecruitingPrimary

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

NCT06904989Not ApplicableRecruitingPrimary

A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices

NCT06745011Enrolling By InvitationPrimary

Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System

NCT05560555Completed

Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

NCT03373370CompletedPrimary

Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology

NCT04201418Completed

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

NCT02706314Completed

Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.

NCT02566941Not ApplicableWithdrawnPrimary

Neuromuscular Electrical Stimulation in the Critically Ill

NCT00723918Phase 2Withdrawn

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT01450163Phase 3Completed

Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy

NCT02442986Completed

Neurological Outcome in Surgical and Non-surgical Septic Patients

NCT02846844CompletedPrimary

Patients With Chemotherapy-induced Polyneuropathy Are Treated With an Integrated Program Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training

NCT02666456Unknown

The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain

NCT00832572Phase 4Terminated

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT01302275Phase 4CompletedPrimary

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain

NCT02033057Phase 4UnknownPrimary

Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.

Scroll to load more

Research Network

Activity Timeline